Amgen Inc. history, profile and corporate video

 Amgen Inc. (Amgen) is a biotechnology medicines company. The Company discovers, develops, manufactures and markets medicines for illnesses. It focuses solely on human therapeutics and concentrates on medicines based on cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, inflammation and nephrology. In addition to the Company’s marketed products, it has product candidates in mid- to late-stage development in a range of therapeutic areas, including oncology, hematology, inflammation, bone health, nephrology, cardiovascular and general medicine, which includes neuroscience. On March 4, 2011, the Company acquired BioVex Group, Inc. On April 7, 2011, it acquired Laboratorio Quimico Farmaceutico Bergamo Ltda (Bergamo). In June 2012, the Company acquired more than 99% of the Mustafa Nevzat Pharmaceuticals. In July 2012, the Company acquired KAI Pharmaceuticals, a privately held company based in South San Francisco.”

“Amgen History

The word AMGen is a portmanteau of the company’s original name, Applied Molecular Genetics, which became the official name of the company in 1983 (three years after incorporation and coincident with its initial public offering). The company’s first chief executive officer, from 1980, was George B. Rathmann, followed by Gordon M. Binder in 1988, followed by Kevin W. Sharer in 2000.Robert A. Bradway became Amgen’s president and chief executive officer in May 2012 following Sharer’s retirement.

The company has made at least five major corporate acquisitions.

In June 2013, Amgen offered to buy the shares of Onyx Pharmaceuticals for $120 per share, sending Onyx shares up by around 30% after the news was announced.”

*Information from Forbes.com and Wikipedia.org

**Video published on YouTube by “Amgen